Medpace Holdings Inc (MEDP)
NASDAQ:MEDP
Want to see MEDP full AI Analyst Report?
MEDP Stock Chart & Stats
$520.60
$7.21(2.08%)
At close: 4:00 PM EST
$520.60
$7.21(2.08%)
Day’s Range― - ―
52-Week Range$305.69 - $628.92
Previous CloseN/A
Volume64.09K
Average Volume (3M)297.46K
Market Cap
$13.52B
Enterprise Value$12.52B
Total Cash (Recent Filing)$652.68M
Total Debt (Recent Filing)$122.26M
Price to Earnings (P/E)31.6
Beta1.15
Next Earnings
Jul 22, 2026EPS Estimate
3.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)16.24
Shares Outstanding28,559,689
10 Day Avg. Volume269,075
30 Day Avg. Volume297,459
Financial Highlights & Ratios
PEG Ratio1.82
Price to Book (P/B)35.29
Price to Sales (P/S)6.40
P/FCF Ratio23.76
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue4.68
Enterprise Value/Gross Profit16.09
Enterprise Value/Ebitda20.88
Forecast
1Y Price Target
$452.22Price Target Upside-13.13% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)16.99
Revenue Forecast (FY)$2.77B
Bulls Say, Bears Say
Bulls Say
Strong Free Cash Flow GenerationMedpace’s very strong and consistent free cash flow (TTM ~$745M) and near‑1.0x FCF-to-net-income conversion provide durable financial flexibility. High FCF supports reinvestment, debt service, opportunistic buybacks or M&A and cushions operating cycles, underpinning long-term capital allocation optionality.
Healthy Margins And Scalable ProfitabilityMargins are robust for a CRO and have meaningfully improved since 2021, reflecting operational scale and pricing/efficiency benefits. Durable mid‑teens-plus margins provide earnings resilience if top-line growth moderates and give scope for sustained cash generation per incremental revenue.
Stronger Governance And Leadership ContinuityRemoval of supermajority provisions and clarified special-meeting rights increases accountability and aligns governance with shareholders. Coupled with internal promotions and an orderly presidential transition, this implies continuity in operations and lower execution risk over the medium term.
Bears Say
Elevated Cancellations And Sub‑1 Book‑to‑billPersistent cancellations and a net book-to-bill below 1 materially reduce revenue visibility and can lead to underutilized capacity. If cancellations continue, revenue conversion and backlog dynamics may remain volatile, pressuring medium-term growth and operational planning.
Declining Beyond‑12‑month Backlog CoverageA multi-quarter drop in >12‑month backlog coverage signals weaker long‑range opportunity flow and pipeline depth. This structural backlog erosion reduces medium-term revenue visibility and increases reliance on short‑term wins to sustain growth, raising execution risk if RFPs remain soft.
Customer Concentration RiskHigh revenue concentration among a few clients makes results sensitive to individual sponsor reprioritizations or trial cancellations. Concentration amplifies downside when key customers delay or cancel programs, a structural risk to predictable revenue conversion and backlog stability.
Medpace Holdings News
MEDP FAQ
What was Medpace Holdings Inc’s price range in the past 12 months?
Medpace Holdings Inc lowest stock price was $305.69 and its highest was $628.91 in the past 12 months.
What is Medpace Holdings Inc’s market cap?
Medpace Holdings Inc’s market cap is $13.52B.
When is Medpace Holdings Inc’s upcoming earnings report date?
Medpace Holdings Inc’s upcoming earnings report date is Jul 22, 2026 which is in 27 days.
How were Medpace Holdings Inc’s earnings last quarter?
Medpace Holdings Inc released its earnings results on Apr 22, 2026. The company reported $4.28 earnings per share for the quarter, beating the consensus estimate of $3.921 by $0.359.
Is Medpace Holdings Inc overvalued?
According to Wall Street analysts Medpace Holdings Inc’s price is currently Overvalued.
Does Medpace Holdings Inc pay dividends?
Medpace Holdings Inc does not currently pay dividends.
What is Medpace Holdings Inc’s EPS estimate?
Medpace Holdings Inc’s EPS estimate is 3.98.
How many shares outstanding does Medpace Holdings Inc have?
Medpace Holdings Inc has 28,559,689 shares outstanding.
What happened to Medpace Holdings Inc’s price movement after its last earnings report?
Medpace Holdings Inc reported an EPS of $4.28 in its last earnings report, beating expectations of $3.921. Following the earnings report the stock price went down -22.625%.
Which hedge fund is a major shareholder of Medpace Holdings Inc?
Currently, no hedge funds are holding shares in MEDP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medpace Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$452.22 (-13.13% Downside)
$452.22 (-13.13% Downside)
Blogger Sentiment
Bullish
MEDP Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 318.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
53.40%
12-Months-Change
Fundamentals
Return on Equity
120.89%
Trailing 12-Months
Asset Growth
12.24%
Trailing 12-Months
Company Description
Medpace Holdings Inc
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
MEDP Company Deck
MEDP Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call showed strong underlying financial performance in Q1 — double-digit revenue and EBITDA growth, healthy cash generation, and a sizable backlog — and management reaffirmed full-year guidance. However, elevated and persistent cancellations, weaker gross bookings/RFPs and a multi-quarter decline in beyond-12-month backlog coverage are meaningful near- to medium-term risks to sequential growth. Management pointed to a good win rate and initiatives to improve pipeline conversion, but the cadence and durability of that improvement remain uncertain.View all MEDP earnings summariesMEDP Revenue Breakdown
98.00% U.S.
2.00% Other
MEDP Stock 12 Month Forecast
Average Price Target
$452.22
▼(-13.13% Downside)
Technical Analysis
Ownership Overview
19.42% Insiders
21.26% Mutual Funds
23.65% Other Institutional Investors
13.32% Public Companies and
Individual Investors